Novo Nordisk will slash U. S. list prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 50% starting next year, the Danish drugmaker said on Tuesday.

Participants taking the highest dose of Eli Lilly's new GLP-1 drug lost an average of 28. 7% of their body weight in a late-stage trial, putting it on track to be a heavyweight in the crowded world of weight-loss and diabetes treatments.